Janus Henderson Group PLC grew its stake in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 16.1% in the fourth quarter, Holdings Channel reports. The fund owned 1,817,474 shares of the biotechnology company’s stock after purchasing an additional 251,452 shares during the period. Janus Henderson Group PLC owned 0.10% of Ligand Pharmaceuticals worth $189,544,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of LGND. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Ligand Pharmaceuticals by 105.6% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,214 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 1,137 shares during the last quarter. Guggenheim Capital LLC raised its stake in Ligand Pharmaceuticals by 20.7% during the fourth quarter. Guggenheim Capital LLC now owns 26,015 shares of the biotechnology company’s stock worth $2,713,000 after purchasing an additional 4,453 shares during the period. Maverick Capital Ltd. purchased a new position in Ligand Pharmaceuticals during the fourth quarter worth about $1,720,000. Oxford Asset Management LLP purchased a new stake in shares of Ligand Pharmaceuticals in the 4th quarter valued at approximately $409,000. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Ligand Pharmaceuticals by 18.1% during the 4th quarter. Thrivent Financial for Lutherans now owns 528,472 shares of the biotechnology company’s stock worth $55,114,000 after buying an additional 81,109 shares during the last quarter.
In other Ligand Pharmaceuticals news, COO Matthew W. Foehr sold 7,225 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $110.00, for a total value of $794,750.00. Following the sale, the chief operating officer now owns 160,968 shares of the company’s stock, valued at $17,706,480. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.40% of the stock is currently owned by company insiders.
Several analysts have recently commented on the stock. Roth Capital reduced their price target on shares of Ligand Pharmaceuticals from to and set a “buy” rating on the stock in a research report on Monday, February 10th. ValuEngine upgraded Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 1st. HC Wainwright reissued a “buy” rating and set a $237.00 target price on shares of Ligand Pharmaceuticals in a research note on Wednesday, February 12th. Benchmark restated a “buy” rating and issued a $135.00 target price on shares of Ligand Pharmaceuticals in a research report on Friday, February 28th. Finally, Argus lowered Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $153.17.
Shares of LGND opened at $69.91 on Thursday. Ligand Pharmaceuticals Inc. has a 1-year low of $57.24 and a 1-year high of $130.50. The stock has a market cap of $1.22 billion, a PE ratio of 2.38, a P/E/G ratio of 2.18 and a beta of 1.18. The firm has a 50-day simple moving average of $92.32 and a two-hundred day simple moving average of $99.90. The company has a debt-to-equity ratio of 0.85, a current ratio of 66.09 and a quick ratio of 65.66.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Thursday, February 6th. The biotechnology company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.64 by $0.07. The firm had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.30 million. Ligand Pharmaceuticals had a net margin of 523.19% and a return on equity of 4.34%. The business’s revenue for the quarter was down 54.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.70 EPS. As a group, sell-side analysts expect that Ligand Pharmaceuticals Inc. will post 2.27 earnings per share for the current fiscal year.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Featured Article: Quiet Period
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.